3 High-Yield Dividend Stocks Paying 5% or More That Are Worth Buying Now

The article highlights dividend durability across Altria, Realty Income, and Pfizer rather than a single earnings catalyst: Altria has raised its dividend 57 straight years and recently increased it by 3.9%, with nearly a 6% forward yield supported by price hikes, cost cuts since 2024, and smokeless/nicotine pouches. Realty Income offers a 5.1% forward yield paid monthly, with average dividend growth of 4.1% since its 1994 IPO. Pfizer’s forward yield is ~7.1% (framed as a potential “yield trap”), but the piece cites a rebound with 2026Q1 non-COVID sales up 7% YoY and 2026 adjusted earnings guidance of $2.80–$3.00 per share versus $1.72 annual dividends.

Analysis

The market is likely overfocusing on yield level and underfocusing on which cash flows are actually compounding versus merely being redistributed. MO’s near-term durability is a function of pricing power plus mix shift into reduced-risk products, but the bigger second-order issue is whether the category becomes commoditized faster than management can offset cigarette erosion; if that happens, the dividend stays intact for a while but the equity multiple should keep compressing. PM is the cleaner way to express the nicotine-pouch secular theme if investors want growth plus pricing power, while MO remains more of a defensive cash-yield vehicle than a true compounder.

O is not a yield story so much as a rate-duration story. If Treasury yields drift lower over the next 1-3 months, REITs with visible rent escalators should re-rate faster than the broader market; if rates stay sticky, the dividend is fine but valuation upside is capped. The hidden risk is refinancing/cap-rate spread pressure: even modest spread widening can offset several quarters of dividend growth, so the trade works only if the macro path cooperates.

PFE is the most interesting contrarian setup because the market still prices it like a post-COVID ex-growth orphan, yet cash flow coverage gives it time to self-help. The consensus is missing that the dividend itself is not the problem; the issue is whether pipeline execution can replace shrinking high-margin revenue before patent cliffs fully hit. That makes PFE a months-to-years rerating story, but only if 2026 earnings guidance holds and non-COVID sales keep inflecting; otherwise, the yield trap narrative reasserts itself quickly.

Key Decisions for Investors

• Long O on pullbacks only if the 10Y Treasury starts trending below 4.25%; target a 6-12 month re-rating from lower rates, but cut if rates stay above 4.5% or cap rates widen.
• Prefer PM over MO for exposure to oral nicotine; use a long PM / short MO pair for 3-6 months to capture category leadership while hedging legacy cigarette decline risk.
• Do not chase MO as a pure yield play; if buying, require a forward yield premium plus evidence that pouch growth offsets volume erosion. Falsify if U.S. pouch share or pricing decelerates for two consecutive quarters.
• Consider a small long PFE position as a contrarian re-rating trade, but size it as a watchlist name rather than core holding until 2026 EPS guidance and non-COVID sales trend confirm stabilization.
• If forced into a defensive income basket, prefer O + PFE over MO: O for rate-sensitive dividend compounding, PFE for optionality on post-COVID normalization; avoid overconcentration in any single high-yield name.